| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC1965 |
| Trial ID | NCT03651128 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Abecma|bb2121|BMS-986395|Idecabtagene vicleucel|ide-cel |
| Location approved | US, Canada, EU, UK, Japan, Israel, Switzerland |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) |
| Year | 2018 |
| Country | United States |
| Company sponsor | Celgene |
| Other ID(s) | BB2121-MM-003|U1111-1217-9988|2018-001023-38 |
| Cohort 1 | |||||||||||||
|
|||||||||||||